#StemEdit
LightNews LightNews
reprocell.bsky.social
Our StemEdit™ Human iPSC lines are engineered with a genome editing technology using a proprietary nuclease system.

• 𝗕𝟮𝗠 𝗛𝗼𝗺𝗼𝘇𝘆𝗴𝗼𝘂𝘀 𝗞𝗻𝗼𝗰𝗸𝗼𝘂𝘁: Suppresses HLA class I expression.

• 𝗕𝟮𝗠/𝗖𝗜𝗜𝗧𝗔 𝗛𝗼𝗺𝗼𝘇𝘆𝗴𝗼𝘂𝘀 𝗗𝗼𝘂𝗯𝗹𝗲 𝗞𝗻𝗼𝗰𝗸𝗼𝘂𝘁: Suppresses HLA class I & II expression.

Learn more: hubs.li/Q03t0ygM0
June 23, 2025 at 10:38 AM
laotiantimes.com.web.brid.gy
REPROCELL Launches StemEdit – Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ — REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready […]
laotiantimes.com
January 28, 2026 at 3:17 PM
longtail-news.bsky.social
Feed: "Newswise: Latest News"
By: REPROCELL USA on Wednesday, January 28, 2026
REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing Tools
REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA).
www.newswise.com
January 29, 2026 at 12:41 AM
medcloudinsider.bsky.social
REPROCELL launched StemEdit, a clinical gene-editing service using OpenCRISPR-1 to deliver precise gene-edited iPSC lines suitable for both preclinical and clinical workflows.

Here’s what it is and why it matters: https://ow.ly/cWjk50Y9flU

#CRISPR #GeneEditing #iPSC #Biotech #AI
Reprocell Launches StemEdit Services to Advance Clinical Gene Editing With AI-Designed Tools -- MedCloudInsider
New offering combines iPSC technology and AI-driven editing design to support translational and clinical research.
ow.ly
February 5, 2026 at 3:01 PM
newsen.bsky.social
REPROCELL Unveils StemEdit: Pioneering AI-Driven Gene Editing for Clinical Applications#USA#Beltsville#REPROCELL#StemEdit#OpenCRISPR-1
REPROCELL Unveils StemEdit: Pioneering AI-Driven Gene Editing for Clinical Applications
REPROCELL's introduction of StemEdit marks a significant advancement in clinical gene editing, facilitating safer, scalable solutions for cell therapy developers.
third-news.com
January 28, 2026 at 2:59 PM
l2plabs.bsky.social
REPROCELL startet GMP Master Cell Bank-Produktion für klinische iPSCs
Integrierter Arbeitsablauf einschließlich klinischer Seed-Produktion und StemEdit-Geneditierungsservices BELTSVILLE, Maryland, 3. März 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) gab heute den Start seines GMP-konformen (Good Manufacturing Practice) Master Cell Bank (MCB)...
dlvr.it
March 3, 2026 at 2:12 PM
l2plabs.bsky.social
REPROCELL lance la fabrication de banques de cellules maîtresses conformes aux BPF pour les iPSC cliniques
Le flux de travail intégré comprend la production de semences cliniques et les services d'édition génétique StemEdit BELTSVILLE, Maryland, 3 mars 2026 /PRNewswire/ -- REPROCELL (TYO : 4978) a annoncé aujourd'hui le lancement de son service de fabrication de cellules souches pluripotentes...
dlvr.it
March 3, 2026 at 2:03 PM
l2plabs.bsky.social
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service...
dlvr.it
March 3, 2026 at 2:03 PM
bioinformant.bsky.social
Congrats to the REPROCELL team on launching its new StemEdit Platform, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system.

Read more: bioinformant.com/reprocell-st...

#ipscells #geneediting #ai
March 16, 2026 at 12:12 AM
bioinformant.bsky.social
REPROCELL Introduces StemEdit Platform: AI-Designed Genome Editors & Hypoimmune iPSC Lines - bioinformant.com/reprocell-st...

@reprocell.bsky.social
REPROCELL Introduces StemEdit Platform AI-Designed Genome Editors & Hypoimmune iPSC Lines | BioInformant
REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates...
bioinformant.com
March 9, 2026 at 3:54 PM
reprocell.bsky.social
The aim of our new AI-designed StemEdit gene editing platform is simple: make high-precision genome editing more reliable and reproducible for research and future clinical use. Reducing IP complexity and commercial risk helps developers move faster with confidence.

www.reprocell.com/gene-editing...
February 2, 2026 at 10:22 AM
reprocell.bsky.social
REPROCELL now offers our gene-engineered 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖𝘀 (𝗕𝟮𝗠 𝗼𝗿 𝗱𝘂𝗮𝗹 𝗕𝟮𝗠 + 𝗖𝗜𝗜𝗧𝗔 𝗸𝗻𝗼𝗰𝗸𝗼𝘂𝘁𝘀) in combination with the unmodified parental StemRNA™ iPSC line—a bundle ideal for robust experimental design.

👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.

🌐 hubs.li/Q03GqzMM0
StemEdit Hypoimmune iPSCs
Discover REPROCELL's StemEdit™ hypoimmune iPSC lines, enabling advanced immune research and clinical applications with high-quality genome editing technology and regulatory-compliant cell lines.
hubs.li
September 30, 2025 at 12:45 PM
reprocell.bsky.social
A New Bundle: StemEdit™ Hypoimmune iPSCs (HLA-Class I or I+II knockouts) plus unmodified matched StemRNA™ parental line (research/clinical-grade version).

Visit: hubs.li/Q03D70k10
Contact: 𝗶𝗻𝗳𝗼-𝘂𝘀@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹𝘂𝘀𝗮.𝗰𝗼𝗺
August 18, 2025 at 2:13 PM
reprocell.bsky.social
Why 𝗦𝘁𝗲𝗺𝗘𝗱𝗶𝘁 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖 𝗹𝗶𝗻𝗲𝘀 stand out?

-Consistent HLA suppression.
-𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗦𝘁𝗲𝗺𝗘𝗱𝗶𝘁 𝗴𝗲𝗻𝗼𝗺𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴: precise, efficient & licensable.
-𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝗴𝗿𝗮𝗱𝗲 𝗽𝗮𝗿𝗲𝗻𝘁 𝗹𝗶𝗻𝗲 line meets 𝗙𝗗𝗔/𝗘𝗠𝗔/𝗣𝗠𝗗𝗔.
-𝗡𝗼 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 𝗳𝗼𝗿 𝗯𝗮𝘀𝗶𝗰 𝘂𝘀𝗲; commercial/clinical licensing available.

Learn more: hubs.li/Q03w11Cs0
July 7, 2025 at 1:12 PM
reprocell.bsky.social
REPROCELL introduces 𝗦𝘁𝗲𝗺𝗘𝗱𝗶𝘁™ Human iPSC HLA Class 1 & 2 Knockout Lines! These hypoimmune iPSC lines, powered by StemEdit™, enable groundbreaking research in immune-compatible therapies. Hear our CEO Dr. Chikafumi Yokoyama in our latest press release: www.reprocell.com/news/reproce...
May 9, 2025 at 8:23 AM